We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Provence Technologies and Provepharm Invest EUR 4 Million in their New Head Office
News

Provence Technologies and Provepharm Invest EUR 4 Million in their New Head Office

Provence Technologies and Provepharm Invest EUR 4 Million in their New Head Office
News

Provence Technologies and Provepharm Invest EUR 4 Million in their New Head Office

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Provence Technologies and Provepharm Invest EUR 4 Million in their New Head Office"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Provence Technologies and its subsidiary Provepharm have announced an investment of EUR 4 million to build their new head office in Marseille.

Provence Technologies and its subsidiary Provepharm will move into a new building of nearly 1,600 square metres, three times the floor space currently used. The site will accommodate all thirty staff currently employed by the group.

The building has been fitted with equipment to create a dedicated chemical analysis facility. The installation of a kilo lab will increase the group's capacity for synthesis. Provence Technologies can now make the link between preclinical and clinical phases for its clients and scale up for production by the kilogram.

The increased floor space means that staff numbers at the group can expand up to three-fold in the medium term, to sustain strong growth in the business (Provepharm has expanded by 2,000 per cent in five years).

Michel Feraud, chairman and CEO of Provence Technologies Group said: “The new facilities mean that we can continue with our in-house R&D programs. I would like to acknowledge the involvement of all our staff and the support provided by our partners. They have really helped the group to reach the next level of development.”

An incubator specifically for fledgling health care industry companies
The EUR 4 million investment will also fund the launch of a specialist incubator for the health care sector. This is something of a rare step for an SME.

More than 200 square metres of the new head office will be given over to incubating and supporting innovative projects that synergize with the Provence Technologies and Provepharm businesses. The first projects could be up and running within the coming year and will benefit from the facilities and cross-functional skills within the group, as well as its network of commercial, financial and institutional partners.

“Having been housed in a leading-edge technology park where we were able to develop fully, we now want to give fledgling businesses in the health care industries every chance of success, to help them flourish and develop their ideas,” explains Michel Feraud. “It is often difficult for a start-up to get off the ground and find the right support to grow their business. Access to the experience of Provence Technologies Group's staff will be a tremendous asset for these entrepreneurs.”

Advertisement